Texas Oncology (http://www.texasoncology.com) is one of the nation’s leading cancer treatment networks, offering experienced physicians, advanced technologies, clinical research, and leading-edge treatments to patients in the fight against cancer.
With more than 300 physicians providing care at more than 100 sites of service throughout communities in Texas, New Mexico, and Oklahoma, Texas Oncology brings the power and resources of a world-class network to bear for cancer patients and their families every day. Celebrating its 25-year anniversary in 2011, Texas Oncology treats more Texans with cancer than any other provider in the state.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/texas-oncology/46947/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and haemodynamic monitoring, announced the results of a pivotal clinical study of high-risk surgical patients with severe aortic stenosis treated in Cohort A of The PARTNER Trial. These data demonstrate that the study achieved its primary endpoint at one year, concluding that survival of patients treated with the Edwards SAPIEN transcatheter aortic valve was equivalent to those treated with surgical aortic valve replacement. The data were presented at the American College of Cardiology’s (ACC) 60th Annual Scientific Session & Expo in New Orleans, LA, USA.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/edwardslifesciences/48895/
Go to http://www.manageyourtreatment.org for more information.
Cancer has touched the lives of all of us. Each year, it takes the lives of more than half a million Americans and seven million people worldwide.
Cynthia Nixon and Edie Falco will appear in this PSA to encourage cancer patients to win back some control in their lives by managing their treatment. In their role as the campaign ambassadors, Falco and Nixon appear to encourage people to better understand their options and provide support for managing their care.
Could migraine patients be doing more to get the most out of their medical visits? According to a new national survey released by the National Headache Foundation (NHF) and GlaxoSmithKline, the answer is yes. For the nearly 30 million migraine sufferers in the U.S., including six million treating with prescription medication, these survey results may have important implications.
The survey, conducted online in November 2010 by Harris Interactive, included 1,218 diagnosed migraine patients taking prescription medications for their migraine attacks as well as 533 physicians who treat between five and 10 migraine patients per week. The findings revealed disparities between what patients and physicians each reported typically discussing during office visits.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/glaxosmithkline/48596/
“Explore Your Treatment Options,” a new multimedia ad campaign announced today by the U.S. Department of Health and Human Services’ Agency for Healthcare Research and Quality (AHRQ) and the Ad Council, encourages patients to become more informed about their options before choosing a treatment for a health condition or illness.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/50583/
Today, politicians, patients and health and work experts of the Fit for Work Europe Coalition added their voices to national advocates from across Europe for their countries to take bold steps to reduce the staggering €240 billion economic burden of chronic musculoskeletal disorders (MSDs) to European society.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/fitforwork/52154/
Boston Scientific Corporation (NYSE: BSX) introduces its CardioTeach™ iPad® app, an industry-first, free educational resource to help healthcare professionals better educate patients and caregivers about therapy options related to cardiovascular and peripheral diseases, specifically atrial and ventricular arrhythmias, coronary artery disease, heart failure, heart rhythm disorders and peripheral vascular disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/43509-boston-scientific-cardioteach-ipad-app
WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced its new WebMD Pain Coach™ for iPhone, a unique free mobile application for consumers and patients living with chronic pain. As the leader in mobile health, WebMD provides trusted health information anytime and anywhere with its mobile web and applications for consumers and physicians. The new WebMD Pain Coach™ app builds on WebMD’s market-leading mobile applications through a holistic approach that helps users create a balanced lifestyle.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57975-webmd-launches-unique-new-mobile-app-for-those-living-with-chronic-pain
In support of American Diabetes Month®, Colgate Total® is working with the American Diabetes Association to educate patients about diabetes and gum disease and to empower them to help take charge of their diabetes.
A recent survey conducted by Harris Interactive on behalf of Colgate Total® about oral health reveals a lack of awareness about the various health issues associated with diabetes. More than one third of all respondents (36%) are not aware of the link between diabetes and oral health and are less likely to associate oral health issues with diabetes than almost all other health conditions related to diabetes. More than half (54%) report one or more symptoms of gum disease – yet 67% do not discuss their oral health with their doctor.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58614-colgate-total-american-diabetes-association-oral-health-and-diabetes
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
Joerns Healthcare has launched the Dolphin Fluid Immersion Simulation® system that more effectively prevents and treats pressure-related injuries than other surfaces. This patented technology simulates the effect of floating in water for patients on hospital beds, stretchers, and in wheel chairs. The Dolphin technology continually adjusts to the patient’s body, promoting tissue perfusion and oxygenation, and minimizing injury related to compromised blood flow. The Dolphin is also proven to accelerate healing of advanced stage or multiple pressure ulcers, muscle flaps, skin grafts, burns and other wound conditions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58463-joerns-dolphin-fluid-immersion-simulation-system-pressure-related-injuries
Novo Nordisk, a world leader in diabetes care, today kicked off the first NovoLog® Community Star contest. As part of the program, type 2 diabetes patients successfully managing their blood sugar with NovoLog® (insulin aspart [rDNA origin] injection) are invited to visit www.novolog.com and tell us how they’re giving back to their local communities.
Now through March 15, NovoLog® patients can submit their story and photo online for the chance to be crowned a NovoLog® Community Star. Finalists will be selected by a panel of judges, and each will receive a $5,000 donation to a local diabetes-related organization of their choice. One grand prize winner will also receive a one-year online subscription to Weight Watchers® to help with their diabetes management.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59947-novo-nordisk-first-novolog-community-star-contest-type-2-diabetes-patients
